Precision Neuroscience Secures $102 Million Funding for BCI Support
Precision Neuroscience secured a big win by raising an impressive $102 million in funding for its brain-computer interface (BCI) technology. Leading the round was General Equity Holdings, alongside B Capital, Duquesne Family Office, the investment firm of Stanley F. Druckenmiller, and Steadview Capital, who collectively pushed the company’s total capital raised to $155 million. Precision Neuroscience now stands tall amongst the best-funded companies in the escalating BCI industry.
The funding boost will drive the expansion of their team, fuel advancements in clinical research, and enable further developments of their AI-powered brain implant. The Layer 7 cortical interface by Precision Neuroscience features an ultra-thin film with 1,024 electrodes that flexibly conform to the brain’s surface, coming in at just a fifth of the thickness of a human hair.
The primary goal of this device is to assist users with severe paralysis in operating electronic devices, like computers and smartphones, solely through their thoughts. Co-founder and CEO of Precision Neuroscience, Michael Mager, shared, “Our initial focus is on severe spinal cord injury, stroke, ALS, among others, with the vision to create a highly safe and inclusive product for treating a wide range of neurological conditions. This funding represents a significant step toward our mission.”
Notably, a number of noteworthy companies like Neuralink and Synchron are also working in this space, reflecting the growing relevance of BCI technology for broader medical applications. As we look ahead at the future of BCI and neurotech companies, Precision Neuroscience’s success signifies a strong foothold in this exciting and transformative field.
